Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

22.34 -0.10 (-0.42%)
Streaming Delayed Price Updated: 12:03 PM EDT, Apr 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
The State of Weight Loss Drugs
Via The Motley Fool
Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations
BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key data updates expected in 2025. 
Via Benzinga
Exposures COVID-19
BioNTech Surpasses Q4 Revenue Estimates
BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue. 
Via The Motley Fool
3 Reasons PFE is Risky and 1 Stock to Buy Instead
Over the past six months, Pfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain. This might have investors contemplating their next... 
Via StockStory
Topics Stocks
Exposures US Equities
3 Top Dividend Stocks to Buy in March
Via The Motley Fool
Pfizer's Options: A Look at What the Big Money is Thinking
Via Benzinga
1 Stock Down 43% That Looks Too Cheap to Ignore
Via The Motley Fool
Milestone Merger Payment with Predictive Oncology to Advance AI-Driven Biomarker Discovery & Precision Medicine in Cancer & Beyond: Stock Symbol: RENB
$RENB Secures $15 Million in New Equity to Support Operations Towards Revolutionizing Healthcare with $POAILOS ANGELES - March 3, 2025 - PRLog -- Developing AI and Biotechnology Platforms for Early... 
Via PRLog
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Why Moderna Stock Has Surged 20% This Week Despite Mixed News
Recent news has been mixed with a patent win and loss in Germany and the U.S. But Moderna stock has risen markedly this week. 
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
The Nasdaq Is Falling: 4 of the Safest Stocks to Buy Right Now
A double-digit percentage decline in Wall Street's highest-flying stock index spells opportunity for value-oriented investors. 
Via The Motley Fool
The Smartest Dividend Stocks to Buy With $2,000 Right Now
There are lots of good dividend stocks to consider stepping into here, but only a few truly great income-producing prospects. 
Via The Motley Fool
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
From Berger Montague
Via GlobeNewswire
3 Ultra-Cheap Dividend Stocks to Buy Right Now
Via The Motley Fool
Pfizer CEO Says Company May Shift Overseas Manufacturing To US Amid Looming Tariff Threats: 'Will The Trump Administration Co-Invest', Asks Analyst
In light of potential tariff threats from President Donald Trump, Pfizer Inc.'s (PFE.N) CEO Albert Bourla has suggested the possibility of shifting the company's overseas manufacturing to its U.S.... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Most active S&P500 stocks in Monday's session
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Monday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
Zoetis (ZTS): Buy, Sell, or Hold Post Q4 Earnings?
Over the past six months, Zoetis’s shares (currently trading at $166) have posted a disappointing 9.6% loss, well below the S&P 500’s 7.6% gain. This was partly driven by its softer quarterly results... 
Via StockStory
Topics Stocks
Exposures US Equities
2 Top Stocks Beaten Down Near 52-Week Lows That Look Like Bargains Now
Via The Motley Fool
From Losing $60K To Running a $100M Business: CEOs Share Their Biggest Lessons
Via Benzinga
3 Dividend Stocks That Are No-Brainer Buys Right Now
Via The Motley Fool
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang
LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts. 
Via Benzinga
Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds
Moderna is under pressure as two of its vaccines hit potential snags. 
Via Investor's Business Daily
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after the bell. Here’s what to look for. 
Via StockStory
Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?
Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound. 
Via MarketBeat
Exposures Product Safety
Corcept (CORT) Q4 Earnings Report Preview: What To Look For
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results tomorrow afternoon. Here’s what you need to know. 
Via StockStory
Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown
Message volume on Stocktwits jumped 2,500%, with retail traders focusing on Summit’s partnership to evaluate ivonescimab in combination with Pfizer’s antibody-drug conjugates for solid tumors. 
Via Stocktwits
Most active S&P500 stocks in Monday's session
Let's have a look at what is happening on the US markets on Monday. Below you can find the most active S&P500 stocks in today's session. 
Via Chartmill
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Bill Gates Says 'Next Pandemic Can Emerge Anywhere' And The World Isn't Prepared: 'We Can't Afford To Get Caught Flat-Footed Again'
Via Benzinga
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
From Berger Montague
Via GlobeNewswire
What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after market hours. Here’s what you need to know. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback